NEW YORK – OrigiMed and Janssen on Friday announced a collaboration to advance precision cancer care in China through real-world data, better patient management, and the development of new drugs and companion diagnostics.
The two companies said in a statement they hope to improve translational research by establishing a real-world evidence database and use artificial intelligence to identify new therapeutic indications and companion diagnostics. They will also optimize clinical trials through OrigiMed's medical e-platform to improve enrollment localization and patient management and follow-up. Finally, the two firms will explore a pilot program aiming to diversify access to innovative drugs.
OrigiMed, based in Shanghai, partners with pharma companies to improve their clinical trials and to develop biomarker-driven drugs and diagnostics. The company has previously partnered with Bayer to develop a next-generation sequencing-based companion diagnostic for Bayer's TRK inhibitor larotrectinib (Vitrakvi) in China.